This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Despite pioneering RNAi drug development and getting four therapies approved, Al...
As Cargo Therapeutics looks for a permanent solution to its troubles, the biotec...
Regenxbio has biomarker data on the first patient younger than 4 years old dosed...
Pfizer will get about $3.3 billion from its final stake sale in Haleon, accordin...
Immunovant will not seek approval for its candidate for the autoimmune disorder ...
Immunovant will not seek approval for its candidate for the autoimmune disorder ...
Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new...
Black Diamond Therapeutics has found a buyer for an early-stage targeted cancer ...
Ampersand Biomedicines, a biotech working on medicines "similar in principle" to...
The British stem cell company bit.bio has reduced its workforce by 25%, impactin...
Following a court order, HHS won't fire more than 2,800 probationary employees i...
With its decadelong US patent for Entresto set to expire in a few months, Novart...
With its decade-long US patent for Entresto set to come to an end in a few month...
Plus, news about Pyxis Oncology, Kiromic BioPharma, TC BioPharm, EnteroBiotix, L...
In a surprise move, the longtime CEO of Stoke Therapeutics is leaving the compan...
A teenage boy who received Sarepta’s Duchenne muscular dystrophy gene therapy El...